The new gold standard for cancer care
With TRP-001, a cutting-edge precision therapeutic designed for both early- and advanced-stage patients, Torpedo Pharmaceuticals AG aims to redefine prostate cancer treatment.
By combining nuclear imaging with targeted radiotherapy, Torpedo Pharmaceutical AG’s groundbreaking treatment aims to deliver superior outcomes.
With a focus on efficacy, safety, and scalability, Torpedo Pharmaceutical AG aims to offer life-saving solutions to the patients with highest medical need.
With TRP-001, a cutting-edge precision therapeutic designed for both early- and advanced-stage patients, Torpedo Pharmaceuticals AG aims to redefine prostate cancer treatment.
By combining nuclear imaging with targeted radiotherapy, Torpedo Pharmaceutical AG’s groundbreaking treatment aims to deliver superior outcomes.
With a focus on efficacy, safety, and scalability, Torpedo Pharmaceutical AG aims to offer life-saving solutions to the patients with highest medical need.
3x
Potentially higher efficacy over existing treatments As compared to 177-Lutetium-PSMA-617, the only commercial prostate cancer RLT
310,000
US Patient
Population p.a.
$25 bn
Addressable
Market
The Global
Cancer Challenge
Cancer has proven to be a formidable challenge to the global healthcare systems and remains a leading cause of death worldwide, accounting for ca. 10 million of deaths (or one in six deaths) every year.
The Global
Cancer Challenge
Cancer has proven to be a formidable challenge to the global healthcare systems and remains a leading cause of death worldwide, accounting for ca. 10 million of deaths (or one in six deaths) every year.
KEY FIGURES
10 million
Annual Deaths Press Releases
20 million
new cancer cases each year Press Releases
$400 bn
Annual Cancer drug R&D
by 2028
https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2024
41%
Of Americans will be
diagnosed with cancer
https://www.cancer.gov/about-cancer/understanding/statistics
Vast white spaces remain in cancer care
Prostate Cancer is the most common cancer in men, with over 3 million men living with the condition in the US alone…
1st
most common cancer in men https://www.cancer.org/cancer/risk-prevention/understanding-cancer-risk/cancer-facts/cancer-facts-for-men.html
2nd
leading cause of cancer-related deaths in men https://www.unitypoint.org/news-and-articles/most-dangerous-cancers-in-men-and-women#:~:text=Lung%20and%20bronchial%20cancer%20causes,in%20both%20men%20and%20women
1 in 8
men will be diagnosed during their life https://www.cancer.org/cancer/risk-prevention/understanding-cancer-risk/cancer-facts/cancer-facts-for-men.html
<35%
five-year survival rate of stage IV patients What Are the Survival Rates for Prostate Cancer? | American Cancer Society
… but for high-risk prostate cancer patients, the treatment is often worse than the disease
Precision medicine is revolutionizing cancer treatment
Radioligand therapy (RLT) is an innovative approach to cancer treatment that delivers targeted radiation directly to tumour cells – to quote Prof. Richard Baum, one of Torpedo Pharmaceuticals AG’s co-founders: “We see what we treat, and we treat what we see.”
RLTs are applied through the so called "theranostics-approach" (a combination of therapy + diagnostics), which informs treatment through nuclear medicine imaging of the RLT target to confirm the cancerous tissue is targeted with a radiation payload.
Precision medicine is revolutionizing cancer treatment
Radioligand therapy (RLT) is an innovative approach to cancer treatment that delivers targeted radiation directly to tumour cells – to quote Prof. Richard Baum, one of Torpedo Pharmaceuticals AG’s co-founders: “We see what we treat, and we treat what we see.”
RLTs are applied through the so called "theranostics-approach" (a combination of therapy + diagnostics), which informs treatment through nuclear medicine imaging of the RLT target to confirm the cancerous tissue is targeted with a radiation payload.
6-12x
More Effective (PR rate) than standard therapy
As measured during the VISION trial by comparing
177-Lutetium-PSMA-617 outcomes to one of the approved standard
therapies
Reference:
https://us.pluvicto.com/about-pluvicto/how-pluvicto-may-help%20
35%
Longer Overall Survival Rates
Longer Overall Survival Rates
Reference:
https://us.pluvicto.com/about-pluvicto/how-pluvicto-may-help%20
4x
Lower discontinuation rate due to side effects
As measured during the VISION trial by comparing
177-Lutetium-PSMA-617 outcomes to one of the approved standard
therapies
Reference:
https://us.pluvicto.com/about-pluvicto/how-pluvicto-may-help%20
6-12x
More Effective (PR rate) than
standard therapy
As measured during the VISION trial by comparing
177-Lutetium-PSMA-617 outcomes to one of the approved standard
therapies
Reference:
https://us.pluvicto.com/about-pluvicto/how-pluvicto-may-help%20
35%
Longer Overall Survival Rates
Longer Overall Survival Rates
Reference:
https://us.pluvicto.com/about-pluvicto/how-pluvicto-may-help%20
4x
Lower discontinuation rate
due to side effects
As measured during the VISION trial by comparing
177-Lutetium-PSMA-617 outcomes to one of the approved standard
therapies
Reference:
https://us.pluvicto.com/about-pluvicto/how-pluvicto-may-help%20
Introducing Torpedo
Torpedo Pharmaceuticals AG is a Swiss biotech company pioneering novel radioligand therapies (RLTs), a precision cancer treatment utilizing the most promising isotope with the potential to surpass the current gold standard.
Introducing Torpedo
Torpedo Pharmaceuticals AG is a Swiss biotech company pioneering novel radioligand therapies (RLTs), a precision cancer treatment utilizing the most promising isotope with the potential to surpass the current gold standard.
Delivering
true Precision Medicine
=
Targeted Approach
161-Tb PSMA I&T is highly precise and preserves healthy tissues, in turn delivering better results with a good safety profile as shown in preclinical studies. https://www.thno.org/v14p1829.pdf
Applied using the theranostic approach, which combines treatment with nuclear imaging, allowing for a fully personalized treatment. https://ejnmmipharmchem.springeropen.com/articles/10.1186/s41181-019-0063-6
Active monitoring supported by a precise insights provided by nuclear medicine scans and collected patient data. https://pmc.ncbi.nlm.nih.gov/articles/PMC6820371/
Mechanism
By using Terbium-161, Torpedo Pharmaceuticals AG will harvest the power of both beta-minus and highly potent Auger electrons, maximizing treatment efficacy. https://pmc.ncbi.nlm.nih.gov/articles/PMC8724898
The combination of beta-minus and Auger electrons delivers ~2.4X higher doses to tumors, as compared to current gold standard 177Lu-PSMA-617 therapy (Novartis).
Torpedo is aiming to set the new gold standard
Terbium-161 has meaningfully outperformed its main competitor across key
endpoints
Reference: https://pmc.ncbi.nlm.nih.gov/articles/PMC6820371/
https://ejnmmipharmchem.springeropen.com/articles/10.1186/s41181-019-0063-6
https://pmc.ncbi.nlm.nih.gov/articles/PMC8724898/
*As compared in vivo in animal models; there are yet no large sample size clinical studies
comparing the two therapies
in animal studies, while
exhibiting a comparable safety profile.
177Lu-PSMA-617
(Novartis)
Efficacy
Radiation
Survival
Safety
Lutetium-177
Element
161Tb-PSMA-I&T
(Torpedo)
3x moreeffective
2x higherradiation
3x lon-termsurvivors
Similarsafety profile
Terbium-161
Betterpotency & access
Download Our
Company Presentation
your name
your email
organization name